BUSI 304 Week 1 Discussion Board Forum 1 Example

Discussion Board Forum 1: Analyzing Medicare Drug Price Negotiation

BUSI 304 Introduction to Health Policy, Discussion Board Forum 1

Thread by [Student Name]

The classmates are composites; the textbook, Scripture and the peer-reviewed articles cited are real.

Medicare spends a large share of its prescription drug budget on a small number of brand-name drugs that have no generic competition. Before 2022, Medicare was barred from negotiating their prices directly. The Inflation Reduction Act changed that by creating the Medicare Drug Price Negotiation Program, and the first ten negotiated prices took effect in 2026. McLaughlin and McLaughlin (2015) describe health policy analysis as an interdisciplinary task that weighs economic, political and ethical considerations together, and this law shows why. A policy that looks like simple arithmetic, paying less for the same drugs, turns out to involve trade-offs among patients, taxpayers, manufacturers and the pharmacies that dispense the drugs.

The economic question is whether negotiation saves money. Jeon et al. (2026) modeled 2026 Part D spending on the first ten drugs and projected $23.8 billion with negotiated prices compared with $26.1 billion without negotiation, a reduction of $2.3 billion, or 8.8%. Savings were larger for drugs with low prior rebates and long remaining exclusivity, and smaller for drugs about to face generic or biosimilar competition. That pattern makes sense: negotiation matters most where no competitor is coming to push prices down. For beneficiaries, lower Medicare spending also matters at the pharmacy counter, because coinsurance for many Part D drugs is calculated on the price.

The political question is how the law emerged after decades of incremental reform. Ramachandran et al. (2026) trace drug pricing policy from the 1960s through the Medicare Modernization Act of 2003, which created Part D without negotiation, to the Inflation Reduction Act, and describe a fragmented system of benchmarks and rebates that made prices hard to see. Each reform solved one problem and created another, which is a lesson for analysts: a new policy enters a system already shaped by earlier ones.

The ethical question is what a fair price is. Scripture condemns dishonest scales and calls a just weight the Lord's delight (English Standard Version Bible, 2001/2016, Proverbs 11:1). A pricing system so opaque that the largest buyer could not bargain is hard to call a just weight. Negotiation does not set a perfect price, but it brings the largest buyer back to the scale. My initial view is that the program is sound policy, provided its unintended effects are monitored.

Reply to Brianna

Brianna, you raised something my thread missed: long-term care pharmacies may lose money on negotiated drugs. Bhardwaj et al. (2026) estimate that reimbursement at the maximum fair price combined with inadequate dispensing fees could reduce these pharmacies' revenue on selected drugs by more than 85%, and that new payment flows may delay reimbursement for businesses operating on thin margins. If those pharmacies close, nursing home residents could lose access to the very drugs the law aims to make affordable. These residents often take many medications at once and depend on pharmacies that package doses for nursing staff, so a closure is not easily replaced by a retail store down the street. Ramachandran et al. (2026) show how earlier drug pricing reforms also produced unexpected consequences, such as the Medicaid best-price rules, which suggests that monitoring and adjustment are a normal part of policy, not a sign of failure.

Paul asked the Philippians to weigh their neighbors' concerns alongside their own (English Standard Version Bible, 2001/2016, Philippians 2:4). Good policy does the same, weighing the interests of small pharmacies alongside those of Medicare and patients. Bhardwaj et al. (2026) propose near-term fixes, such as appropriating funds so manufacturers' refunds reach pharmacies on time, and longer-term moves toward value-based payment. From an administrator's point of view, a nursing home whose pharmacy partner struggles would feel the effect quickly, in delayed deliveries and harder conversations with families. Do you think a higher dispensing fee would be the simplest fix, or would faster refunds matter more to a small pharmacy's survival?

Reply to Kevin

Kevin, you worried that negotiation will reduce the incentive to develop new drugs, especially for rare diseases. Recent evidence suggests the concern may be overstated in some areas, though not dismissed entirely. Innovation depends on expected revenue, and any policy that lowers prices will reduce revenue for some products, so the real question is by how much and for which drugs. Chen et al. (2026) examined 167 high-spending drugs and found that 94% recovered their clinical trial costs within ten years of global launch, and that drugs protected from negotiation as orphan drugs recovered costs as fast as or faster than others. On the other hand, Beinfeld et al. (2025) found that the law's rule delaying negotiation for biologics facing biosimilar competition can change market incentives, and that selecting such drugs may give up larger long-term savings from competition. Both findings point to design details that matter more than the principle of negotiation itself. In policy analysis terms, the question is less whether to negotiate than which drugs to select and when, since those choices determine both savings and incentives. A rule that protects true rare disease research while closing loopholes for blockbuster drugs with a small orphan indication could serve both goals.

Jesus taught that much will be required from those to whom much has been given (English Standard Version Bible, 2001/2016, Luke 12:48). Drug makers have been given patents and public research support; asking for fair prices in return seems consistent with that principle. Would you support negotiation if orphan protections were narrowed to drugs that treat only rare diseases, or do you think any negotiation sends the wrong signal to investors?

References

Beinfeld, M. T., Ghule, P., LaMountain, F., Wong, W., Ko, S., & Chambers, J. D. (2025). The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. Health Affairs Scholar, 3(11), qxaf222. https://doi.org/10.1093/haschl/qxaf222

Bhardwaj, S., Schmutz, H. W., Watanabe, J. H., & Barthold, D. (2026). Challenges of the Inflation Reduction Act for long-term care pharmacy: Examining impact and policy solutions. Journal of Managed Care & Specialty Pharmacy, 32(4), 498-506. https://doi.org/10.18553/jmcp.2026.25312

Chen, J. C., Madsen, C., & Kaltenboeck, A. (2026). The economics of orphan blockbuster drug development. Health Affairs, 45(8), 838-845. https://doi.org/10.1377/hlthaff.2026.00209

English Standard Version Bible. (2016). Crossway. (Original work published 2001)

Jeon, Y. K., Hansen, R. N., Gabriel, N., Martin, K., & Sullivan, S. D. (2026). Spending impact of the first 10 drugs selected for Medicare drug price negotiation in the United States. Value in Health, 29(7), 1228-1234. https://doi.org/10.1016/j.jval.2026.03.010

McLaughlin, C. P., & McLaughlin, C. D. (2015). Health policy analysis: An interdisciplinary approach (2nd ed.). Jones & Bartlett Learning.

Ramachandran, S., Arabshomali, A., & Coster, J. (2026). History of drug pricing reform in the United States: From policy foundations to latest reforms. Health Affairs Scholar, 4(9), qxag216. https://doi.org/10.1093/haschl/qxag216